Our 2020 Blueprint
2
marketed products
4
pending
marketing
applications
marketing
applications
6
clinical-stage
therapeutic
candidates
therapeutic
candidates
8
research
programs
programs
Our “2020 Blueprint” strategy establishes a planned path to transform Blueprint Medicines, by the end of 2020, into a global commercial enterprise focused on delivering a portfolio of precision therapies to patients with cancer and rare diseases. See our press release.
Recent News
Nov 03, 2020
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Events and presentations
Nov 17, 2020
Blueprint Medicines to Present at the Jefferies Virtual London Healthcare Conference
Oct 29, 2020
Q3 2020 Blueprint Medicines Corp Conference Call
Our commitment to patients
At Blueprint Medicines, we work together in pursuit of one common goal: to dramatically improve the lives of people with genomically defined diseases.
Read onPhoto: R.S., living with systemic mastocytosis
Clinical programs
Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.
Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.
Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.
Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.
Meet the Blue Crew
Meet the Blue Crew
Andrew Kim, International Head of Precision Medicine
As Blueprint Medicines’ first International Head of Precision Medicine, my role is to strategically plan and lead outreach to clinical investigators, healthcare providers and laboratories outside the United States to support the company’s portfolio of clinical-stage programs.
Read onWe aspire to pioneer multiple new scientific advances in disease biology and the design of precision therapies. To learn more about our scientific leadership and perspectives, visit The Lens.
Read on
“We ignore traditional boundaries and let science drive us. It’s the only way to revolutionize how we treat cancer.”Jeff Albers,
Chief Executive Officer
“We ignore traditional boundaries and let science drive us. It’s the only way to revolutionize how we treat cancer.”Jeff Albers, Chief Executive Officer
Dare to be different
A strong team embraces different perspectives, opinions and ideas. We believe each level of our company should reflect our team’s diversity—and its excellence.
Read on